(MEDP) Medpace Holdings - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 12.643m USD | Total Return: 49.6% in 12m
Avg Turnover: 131M
EPS Trend: 99.3%
Qual. Beats: 3
Rev. Trend: 98.5%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Medpace Holdings, Inc. (MEDP) is a clinical contract research organization (CRO) providing full-service drug and medical device development across all phases of clinical trials (Phase I–IV). Headquartered in Cincinnati, Ohio, the company operates globally, supporting biotechnology, pharmaceutical, and medical device clients through regulatory affairs, clinical monitoring, and laboratory services.
The company utilizes a full-service outsourcing model, which integrates central laboratory, imaging, and clinical pharmacology services to streamline the development process for small-to-midsize biopharma firms. Unlike diversified competitors, Medpace focuses heavily on specialized therapeutic areas, a strategy common in the Life Sciences Tools & Services sub-industry to maintain high scientific standards during complex regulatory submissions.
Investors can further evaluate these operational metrics and valuation trends on ValueRay. This integrated approach allows the company to manage end-to-end trial execution, including data management and post-marketing support, across six continents.
- Biotech funding levels dictate clinical trial demand and backlog growth trajectory
- Full-service outsourcing model drives industry-leading profit margins and cash flow
- Concentration in small to mid-sized biotech firms increases credit risk exposure
- Global clinical trial expansion accelerates revenue growth in diverse therapeutic areas
- Labor market tightness and wage inflation impact project execution costs and margins
| Net Income: 460.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 6.14 > 1.0 |
| NWC/Revenue: -7.69% < 20% (prev -13.95%; Δ 6.26% < -1%) |
| CFO/TA 0.35 > 3% & CFO 739.2m > Net Income 460.4m |
| Net Debt (-384.3m) to EBITDA (579.9m): -0.66 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (29.0m) vs 12m ago -7.16% < -2% |
| Gross Margin: 29.07% > 18% (prev 31.51%; Δ -2.44% > 0.5%) |
| Asset Turnover: 133.0% > 50% (prev 113.7%; Δ 19.35% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: -0.10 (Total Current Assets 1.14b - Total Current Liabilities 1.35b) / Total Assets 2.13b |
| B: -0.16 (Retained Earnings -336.1m / Total Assets 2.13b) |
| C: 0.28 (EBIT TTM 565.7m / Avg Total Assets 2.01b) |
| D: 0.39 (Book Value of Equity 598.3m / Total Liabilities 1.53b) |
| Altman-Z'' = 1.15 = BB |
| DSRI: 1.07 (Receivables 394.6m/298.2m, Revenue 2.68b/2.16b) |
| GMI: 1.08 (GM 31.51% / 29.07%) |
| AQI: 0.79 (AQ_t 0.34 / AQ_t-1 0.43) |
| SGI: 1.24 (Revenue 2.68b / 2.16b) |
| TATA: -0.13 (NI 460.4m - CFO 739.2m) / TA 2.13b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of June 03, 2026, the stock is trading at USD 445.59 with a total of 298,812 shares traded.
Over the past week, the price has changed by +3.84%,
over one month by +6.85%,
over three months by -2.60% and
over the past year by +49.62%.
Medpace Holdings has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold MEDP.
- StrongBuy: 2
- Buy: 0
- Hold: 10
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 442.8 | -0.6% |
P/E Trailing = 27.8759
P/E Forward = 25.4453
P/S = 4.7204
P/B = 20.43
P/EG = 2.6314
Revenue TTM = 2.68b USD
EBIT TTM = 565.7m USD
EBITDA TTM = 579.9m USD
Long Term Debt = 122.3m USD (estimated: total debt 146.1m - short term 23.8m)
Short Term Debt = 23.8m USD (from shortTermDebt, last quarter)
Debt = 268.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 122.3m
Net Debt = -384.3m USD (calculated: Debt 268.4m - CCE 652.7m)
Enterprise Value = 12.3b USD (12.6b + Debt 268.4m - CCE 652.7m)
Interest Coverage Ratio = unknown (Ebit TTM 565.7m / Interest Expense TTM 0.0)
EV/FCF = 16.61x (Enterprise Value 12.3b / FCF TTM 737.8m)
FCF Yield = 6.02% (FCF TTM 737.8m / Enterprise Value 12.3b)
FCF Margin = 27.55% (FCF TTM 737.8m / Revenue TTM 2.68b)
Net Margin = 17.19% (Net Income TTM 460.4m / Revenue TTM 2.68b)
Gross Margin = 29.07% ((Revenue TTM 2.68b - Cost of Revenue TTM 1.90b) / Revenue TTM)
Gross Margin QoQ = 27.78% (prev 28.98%)
Tobins Q-Ratio = 5.76 (Enterprise Value 12.3b / Total Assets 2.13b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 268.4m)
Taxrate = 19.48% (111.4m / 571.8m)
NOPAT = 455.5m (EBIT 565.7m * (1 - 19.48%))
Current Ratio = 0.85 (Total Current Assets 1.14b / Total Current Liabilities 1.35b)
Debt / Equity = 0.45 (Debt 268.4m / totalStockholderEquity, last quarter 598.3m)
Debt / EBITDA = -0.66 (Net Debt -384.3m / EBITDA 579.9m)
Debt / FCF = -0.52 (Net Debt -384.3m / FCF TTM 737.8m)
Total Stockholder Equity = 380.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.87% (Net Income 460.4m / Total Assets 2.13b)
RoE = 120.9% (Net Income TTM 460.4m / Total Stockholder Equity 380.8m)
RoCE = 112.4% (EBIT 565.7m / Capital Employed (Equity 380.8m + L.T.Debt 122.3m))
RoIC = 67.53% (NOPAT 455.5m / Invested Capital 674.5m)
WACC = 9.45% (E(12.6b)/V(12.9b) * Re(9.65%) + D(268.4m)/V(12.9b) * Rd(0.0%) * (1-Tc(0.19)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -64.44 | Cagr: -4.10%
[DCF] Terminal Value 74.49% ; FCFF base≈659.1m ; Y1≈755.5m ; Y5≈1.11b
[DCF] Fair Price = 504.3 (EV 14.0b - Net Debt -384.3m = Equity 14.4b / Shares 28.6m; r=9.45% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.26 | EPS CAGR: 28.21% | SUE: 1.30 | # QB: 3
Revenue Correlation: 98.48 | Revenue CAGR: 16.21% | SUE: 0.37 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.96 | Chg30d=-2.99% | Revisions=-17% | Analysts=8
EPS next Quarter (2026-09-30): EPS=4.26 | Chg30d=-5.16% | Revisions=-67% | Analysts=8
EPS current Year (2026-12-31): EPS=17.06 | Chg30d=-1.54% | Revisions=-14% | GrowthEPS=+11.7% | GrowthRev=+9.5%
EPS next Year (2027-12-31): EPS=18.56 | Chg30d=-3.29% | Revisions=-29% | GrowthEPS=+8.8% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: -67%